July 1st 2025
A look back at the FDA submissions and regulatory decisions in the pediatric health care space from June 2025.
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies
View More
Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
Navigating the current shortages of pediatric ADHD medications
Understand how to naviate the current shortage of pediatric ADHD medications.
Evaluating prevalence of psychotropic medication in children with type 1 diabetes
October 10th 2023From 2006 to 2019, psychotropic medication use for those with type 1 diabetes (T1D) increased, leading investigators to call for risk-benefit studies, further evaluating effectiveness and improved diabetes care in this population.
Advancements in FDA approvals for pediatric obesity treatment
GLP-1 receptor agonists, used to treat diabetes, are now also being used for obesity in children and adolescents.